David Walsey
Investor Relations Contact bij MEI PHARMA, INC.
Profiel
David A.
Walsey is currently working as the SVP-Corporate Affairs & VP-Investor Relations at MEI Pharma, Inc. He previously worked as the Senior Director-Investor Relations at Sarepta Therapeutics, Inc. From 2005 to 2009, he held the position of Director-Corporate Communications at Arena Pharmaceuticals, Inc. He also served as the Head-Investor Relations & Corporate Communications at Maxim Pharmaceuticals, Inc. and as the VP-Investor Relations & Corporate Communications at Optimer Pharmaceuticals LLC.
Additionally, he worked as the Vice President-Corporate Communications at Lundbeck Seattle BioPharmaceuticals, Inc. Mr. Walsey completed his undergraduate degree at Franklin & Marshall College and his graduate degrees at Brooklyn Law School and New York University School of Law.
Actieve functies van David Walsey
| Bedrijven | Functie | Begin |
|---|---|---|
| MEI PHARMA, INC. | Investor Relations Contact | 01-02-2018 |
Eerdere bekende functies van David Walsey
| Bedrijven | Functie | Einde |
|---|---|---|
| ARENA PHARMACEUTICALS | Public Communications Contact | 01-01-2009 |
| Maxim Pharmaceuticals, Inc. | Public Communications Contact | - |
| ALDER BIOPHARMACEUTICALS, INC. | Investor Relations Contact | - |
| SAREPTA THERAPEUTICS, INC. | Public Communications Contact | - |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Investor Relations Contact | - |
Opleiding van David Walsey
| Franklin & Marshall College | Undergraduate Degree |
| Brooklyn Law School | Graduate Degree |
| New York University School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
| Maxim Pharmaceuticals, Inc. | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
